TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04020575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells
Description: huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D
Description: huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D
Description: huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D
Description: huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D
Study: NCT03690323

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Description: RFA involves the implantation of electrodes directly into the tumor, with the use of intra-operative ultrasound. The electrodes produce a high frequency alternating current, which leads to frictional heating and thus tissue destruction by thermal coagulation and protein denaturation.
Study: NCT03413371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 % ropivacaine with of 2% lidocaine
Description: in group RL patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 % ropivacaine with of 2% lidocaine
Description: in group RL patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 % ropivacaine with of 2% lidocaine
Description: in group RL patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 % ropivacaine with of 2% lidocaine
Description: in group RL patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 % Ropivacaine
Description: in group R patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 % Ropivacaine
Description: in group R patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 % Ropivacaine
Description: in group R patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 % Ropivacaine
Description: in group R patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine
Description: in group B patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine
Description: in group B patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine
Description: in group B patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine
Description: in group B patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
Study: NCT03252678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a book and videos about ACP
Description: A book and three videos about advanced care planning are provided for self-education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a book and videos about pain control
Description: A book and three videos about pain control for cancer patients are provided for self-education
Study: NCT04126525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: dual HER2 blockade in the neoadjuvant setting
Study: NCT01326585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate Injection
Description: 8mg (2cc of 4mg/mL solution), IV solution, 1-time dose during surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: 2cc of 0.9% normal saline, IV injection, 1-time dose during surgery
Study: NCT04583319

Intervention type: DIAGNOSTIC_TEST
Intervention: EasyCov POC
Description: Saliva samples will be collected according to the sampling protocol defined each for EASYCOV test. The EasyCoV test will be performed at the beginning of the study before obtaining the routine RT- PCR test results. The operators performing this test will be blinded from the routine RT-PCR results.

Intervention type: DIAGNOSTIC_TEST
Intervention: EasyCov POC
Description: Saliva samples will be collected according to the sampling protocol defined each for EASYCOV test. The EasyCoV test will be performed at the beginning of the study before obtaining the routine RT- PCR test results. The operators performing this test will be blinded from the routine RT-PCR results.
Study: NCT01665794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab given by intravenous (IV) infusion at assigned dose.
Study: NCT03444688

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Gait Training
Description: Subjects allocated to the CT group will first perform active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. They will then perform conventional gait and balance therapy based on the proprioceptive neuromuscular facilitation (PNF) concept for 15 minutes. They will be given a 5 minutes rest. Finally, the CT subjects will undergo the over-ground gait training with or without aid or orthoses and with manual assistance from senior physiotherapist for 15 minutes, depending on the individual subject's abilities.
Study: NCT03502707

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF Protein 50 mcg
Description: RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.
Study: NCT02055911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
Study: NCT01662050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Bendamustine, Cytarabine.
Description: 6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.
Study: NCT02845154

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bolus purge
Description: complete and uninterrupted purge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent purge
Description: intermittent portal purge
Study: NCT01175330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fish oil emulsion (Omegaven)
Description: Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intralipid
Description: Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
Study: NCT01698554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost formulation A solution
Description: Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost solution 0.03 %
Description: Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of bimatoprost formulation A solution
Description: Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of bimatoprost solution 0.03 %
Description: Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
Study: NCT00595140

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: pegvisomant
Description: growth hormone receptor antagonist pegvisomant in patients´ individual dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination with somatostatin analogue octreotide
Description: s.c., 100µg, one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination with dopamine agonist cabergoline
Description: oral, 0.5mg, one time
Study: NCT03449225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Aided Genetic Education Module
Description: Subjects will be provided with an electronic device to view Computer-Aided Genetic Education Module (CAGEM) software. This is an interactive software designed to provide subjects with tailored information regarding prenatal screening options for carrier status and aneuploidy.
Study: NCT01670097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.~Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.~Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days.
Study: NCT03220737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAXCHORA (Cholera Vaccine, Live, Oral)
Description: VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAXCHORA (Cholera Vaccine, Live, Oral)
Description: VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAXCHORA (Cholera Vaccine, Live, Oral)
Description: VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: VAXCHORA (Cholera Vaccine, Live, Oral)
Description: VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for this study is normal (0.9%) saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for this study is normal (0.9%) saline.
Study: NCT03220737

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for this study is normal (0.9%) saline.
Study: NCT01345461

Intervention type: DEVICE
Intervention: transcutaneous electrical muscle stimulation, (model DS7A, Digitimer, Welwyn, Garden City, Hertfordshire, UK)
Description: two constant current high voltage stimulators delivered ten single stimuli twitches with biphasic square pulses at widths of 300 μs. A train generator was then switched on, triggering the delivery a 35 Hz current in bouts of 3 seconds periods separated by 1-second pause for a total of 40 tetanic contractions. In immediate succession to the tetanic contractions a second series of ten single twitch stimuli ended the protocol.
Study: NCT03444688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait rehabilitation with walker
Description: For WT group, subjects will first go through active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. The main therapy consists of 2 parts with 5 minutes rest in between. During part 1, subjects will be trained on the robotic walker with the help of active body weight support (BWS) and functional electrical stimulation (FES) for 15 minutes with pelvic motion support function and lateral balance function being continuously provided. During part 2, subjects will also receive resistance/assistance forces on top of the BWS and FES training for 15 minutes.
Study: NCT03690323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX
Description: Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.
Study: NCT02064725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium cridanimod
Description: Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).
Study: NCT03963479

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium and Vitamin B6
Description: Magnesium and Vitamin B6 will be given to the enrolled patients for 3 months

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium and Vitamin B6
Description: Magnesium and Vitamin B6 will be given to the enrolled patients for 3 months
Study: NCT03671538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500mg/m2 on day 1 of a 21-day cycle ;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;
Study: NCT00764842

Intervention type: DEVICE
Intervention: Encore CLP® Hip stem
Description: Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
Study: NCT01051388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose PPI (Rabeprazole sodium)
Description: PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose PPI (Rabeprazole sodium)
Description: PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-PPI (Gefarnate)
Description: The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
Study: NCT00592150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenoldopam
Description: The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion for 3 hours
Study: NCT01286844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915A 5mg
Description: Oral powder for dispersion in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915A 10mg
Description: Oral powder for dispersion in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915A 25mg
Description: Oral powder for dispersion in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915A 50mg
Description: Oral powder for dispersion in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915A 100mg
Description: Oral powder for dispersion in water
Study: NCT03290638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR)
Description: Teeth Extraction With Bone Grafting and Membrane
Study: NCT03690323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel plus Gemcitabine
Description: Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus Gemcitabine
Description: Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.
Study: NCT03290638

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Bone Regeneration (GBR)
Description: Teeth Extraction With Bone Grafting and Membrane
Study: NCT01062399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent RAD001 10 mg/day
Description: During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent RAD001 10 mg/day
Description: During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent temozolomide
Description: During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent temozolomide
Description: During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent temozolomide
Description: During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concurrent temozolomide
Description: During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent temozolomide
Description: During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.
Study: NCT01670097

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
Study: NCT01062399

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.
Study: NCT01670097

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirometer
Description: Patient to blow into spirometry machine 1 time a day to test lung function.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spirometer
Description: Patient to blow into spirometry machine 1 time a day to test lung function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phone Calls
Description: Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.
Study: NCT04969562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: Emotional Freedom Technique (EFT, Emotional Freedom Technique) is a psychophysiological interpretation that combines elements of cognitive behavioral therapy (CBT), exposure therapy, and somatic stimulation using acupuncture points.